Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2025 08:32 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery...
December 11, 2025 09:00 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy CHICAGO, Dec. 11, 2025 (GLOBE...
December 04, 2025 09:00 ET | Source: Biofrontera Inc.

Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over treatment area of 240 cm2Completion of this study marks a key milestone...
December 03, 2025 08:00 ET | Source: Beauty Innovation Awards

Saranghae Advanced Brightening Dark Spot Repair Serum Named “Anti-Blemish Product of the Year” By Beauty Innovation

LOS ANGELES, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The 2025 Beauty Innovation Awards today announced K-beauty brand Saranghae’s Advanced Brightening Dark Spot Repair Serum has been selected as...
December 02, 2025 08:45 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT

sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to...
November 26, 2025 08:45 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth

THE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted...
October 22, 2025 10:07 ET | Source: Nkarta, Inc.

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
October 22, 2025 09:25 ET | Source: Neurologic Wellness Institute

What is Dysautonomia? Experts Explain Warning Signs During Awareness Month

Chicago, IL, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Do you experience unexplained dizziness when standing, chronic fatigue that doctors can’t explain, or a racing heart for no apparent reason? You might...
October 14, 2025 08:20 ET | Source: Imunon, Inc.

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on...
October 09, 2025 10:01 ET | Source: Optime Care

Optime Care Terminates Distributor Agreement for Korlym® (mifepristone)

Optime Care Terminates Distributor Agreement for Korlym® (mifepristone)